Drug survival of cyclosporine in the treatment of hand eczema: A multicentre, daily use study

W. A. Christoffers; K. Politiek; P. J. Coenraads; J. Van Der Schaft; M. S. De Bruin-Weller; M. L A Schuttelaar

doi:10.1111/jdv.13057

Drug survival of cyclosporine in the treatment of hand eczema: A multicentre, daily use study

W. A. Christoffers, K. Politiek, P. J. Coenraads, J. Van Der Schaft, M. S. De Bruin-Weller, M. L A Schuttelaar^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

BACKGROUND: Hand eczema is a common condition; it is often chronic and can be difficult to treat. Cyclosporine is used off-label to treat severe hand eczema; however, the evidence for this treatment is scarce.

OBJECTIVE: To examine the drug survival of cyclosporine in a daily practice cohort of patients with chronic hand eczema.

METHODS: This retrospective daily use study included hand eczema patients who were treated with cyclosporine between 01-06-1999 and 01-06-2014 in two Dutch university hospitals. Patient and treatment characteristics were retrospectively collected from medical charts. First treatment episodes were analysed by means of Kaplan-Meier drug survival curves. Possible determinants of drug survival were analysed by Cox regression models. Treatment effectiveness was analysed with a retrospective physician's global assessment.

RESULTS: A total of 102 patients were treated with cyclosporine. The median drug survival rate was 0.86 years (10.3 months). The overall drug survival rate after 6 months, 1, 2 and 3 years were 61.7%, 45.2%, 18.6% and 13.9% respectively. Main reasons for discontinuation were adverse events, especially early in treatment, and ineffectiveness. After 3 months, a good response to treatment was recorded in 62.9% of the patients.

CONCLUSION: Cyclosporine had a median drug survival of 10.3 months. Especially patients with recurrent vesicular hand eczema showed a good treatment response.

Original language	English
Pages (from-to)	63-66
Number of pages	4
Journal	JEADV : journal of the European Academy of Dermatology and Venereology
Volume	30
Issue number	1
DOIs	https://doi.org/10.1111/jdv.13057
Publication status	Published - 1 Jan 2016

Access to Document

10.1111/jdv.13057

Cite this

@article{ccf24975f3774673a417b80dd7581570,

title = "Drug survival of cyclosporine in the treatment of hand eczema: A multicentre, daily use study",

abstract = "BACKGROUND: Hand eczema is a common condition; it is often chronic and can be difficult to treat. Cyclosporine is used off-label to treat severe hand eczema; however, the evidence for this treatment is scarce.OBJECTIVE: To examine the drug survival of cyclosporine in a daily practice cohort of patients with chronic hand eczema.METHODS: This retrospective daily use study included hand eczema patients who were treated with cyclosporine between 01-06-1999 and 01-06-2014 in two Dutch university hospitals. Patient and treatment characteristics were retrospectively collected from medical charts. First treatment episodes were analysed by means of Kaplan-Meier drug survival curves. Possible determinants of drug survival were analysed by Cox regression models. Treatment effectiveness was analysed with a retrospective physician's global assessment.RESULTS: A total of 102 patients were treated with cyclosporine. The median drug survival rate was 0.86 years (10.3 months). The overall drug survival rate after 6 months, 1, 2 and 3 years were 61.7%, 45.2%, 18.6% and 13.9% respectively. Main reasons for discontinuation were adverse events, especially early in treatment, and ineffectiveness. After 3 months, a good response to treatment was recorded in 62.9% of the patients.CONCLUSION: Cyclosporine had a median drug survival of 10.3 months. Especially patients with recurrent vesicular hand eczema showed a good treatment response.",

author = "Christoffers, {W. A.} and K. Politiek and Coenraads, {P. J.} and {Van Der Schaft}, J. and {De Bruin-Weller}, {M. S.} and Schuttelaar, {M. L A}",

note = "{\textcopyright} 2015 European Academy of Dermatology and Venereology.",

year = "2016",

month = jan,

day = "1",

doi = "10.1111/jdv.13057",

language = "English",

volume = "30",

pages = "63--66",

journal = "JEADV : journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Drug survival of cyclosporine in the treatment of hand eczema

T2 - A multicentre, daily use study

AU - Christoffers, W. A.

AU - Politiek, K.

AU - Coenraads, P. J.

AU - Van Der Schaft, J.

AU - De Bruin-Weller, M. S.

AU - Schuttelaar, M. L A

PY - 2016/1/1

Y1 - 2016/1/1

N2 - BACKGROUND: Hand eczema is a common condition; it is often chronic and can be difficult to treat. Cyclosporine is used off-label to treat severe hand eczema; however, the evidence for this treatment is scarce.OBJECTIVE: To examine the drug survival of cyclosporine in a daily practice cohort of patients with chronic hand eczema.METHODS: This retrospective daily use study included hand eczema patients who were treated with cyclosporine between 01-06-1999 and 01-06-2014 in two Dutch university hospitals. Patient and treatment characteristics were retrospectively collected from medical charts. First treatment episodes were analysed by means of Kaplan-Meier drug survival curves. Possible determinants of drug survival were analysed by Cox regression models. Treatment effectiveness was analysed with a retrospective physician's global assessment.RESULTS: A total of 102 patients were treated with cyclosporine. The median drug survival rate was 0.86 years (10.3 months). The overall drug survival rate after 6 months, 1, 2 and 3 years were 61.7%, 45.2%, 18.6% and 13.9% respectively. Main reasons for discontinuation were adverse events, especially early in treatment, and ineffectiveness. After 3 months, a good response to treatment was recorded in 62.9% of the patients.CONCLUSION: Cyclosporine had a median drug survival of 10.3 months. Especially patients with recurrent vesicular hand eczema showed a good treatment response.

AB - BACKGROUND: Hand eczema is a common condition; it is often chronic and can be difficult to treat. Cyclosporine is used off-label to treat severe hand eczema; however, the evidence for this treatment is scarce.OBJECTIVE: To examine the drug survival of cyclosporine in a daily practice cohort of patients with chronic hand eczema.METHODS: This retrospective daily use study included hand eczema patients who were treated with cyclosporine between 01-06-1999 and 01-06-2014 in two Dutch university hospitals. Patient and treatment characteristics were retrospectively collected from medical charts. First treatment episodes were analysed by means of Kaplan-Meier drug survival curves. Possible determinants of drug survival were analysed by Cox regression models. Treatment effectiveness was analysed with a retrospective physician's global assessment.RESULTS: A total of 102 patients were treated with cyclosporine. The median drug survival rate was 0.86 years (10.3 months). The overall drug survival rate after 6 months, 1, 2 and 3 years were 61.7%, 45.2%, 18.6% and 13.9% respectively. Main reasons for discontinuation were adverse events, especially early in treatment, and ineffectiveness. After 3 months, a good response to treatment was recorded in 62.9% of the patients.CONCLUSION: Cyclosporine had a median drug survival of 10.3 months. Especially patients with recurrent vesicular hand eczema showed a good treatment response.

UR - http://www.scopus.com/inward/record.url?scp=84955183116&partnerID=8YFLogxK

U2 - 10.1111/jdv.13057

DO - 10.1111/jdv.13057

M3 - Article

C2 - 25731072

SN - 0926-9959

VL - 30

SP - 63

EP - 66

JO - JEADV : journal of the European Academy of Dermatology and Venereology

JF - JEADV : journal of the European Academy of Dermatology and Venereology

IS - 1

ER -

Drug survival of cyclosporine in the treatment of hand eczema: A multicentre, daily use study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this